Current and future treatments for Alzheimer's disease.
TLDR
Current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials are discussed.Abstract:
Alzheimer’s dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as ‘disease-modifying’ drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulati...read more
Citations
More filters
Journal ArticleDOI
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance
Michael Ewers,Michael Ewers,Cathal Walsh,John Q. Trojanowski,Leslie M. Shaw,Ronald C. Petersen,Clifford R. Jack,Howard Feldman,Arun L.W. Bokde,Gene E. Alexander,Philip Scheltens,Bruno Vellas,Bruno Dubois,Michael W. Weiner,Michael W. Weiner,Harald Hampel +15 more
TL;DR: Short-term conversion to AD is predicted by single marker models to a comparable degree as by multimarker models in amnestic MCI subjects.
Journal ArticleDOI
Current and Future Treatments in Alzheimer Disease: An Update.
TL;DR: A review of disease-modifying therapies for Alzheimer disease can be found in this paper, where the authors discuss potential disease modifying therapies that are currently being studied and potential individualized therapeutic frameworks that can be proved beneficial for patients with AD.
Journal ArticleDOI
Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease.
Xueli Zhang,Yanli Tian,Yanli Tian,Zeng Li,Xiaoyu Tian,Hongbin Sun,Hong Liu,Anna Moore,Chongzhao Ran +8 more
TL;DR: Curcumin-based near-infrared fluorescence imaging probes for detecting both soluble and insoluble amyloid beta (Aβ) species and then an inhibitor that could attenuate cross-linking of Aβ induced by copper are designed and synthesized.
Journal ArticleDOI
The multiplex model of the genetics of Alzheimer’s disease
TL;DR: The multiplex model reflects the combination of some, or all, of these model components (genetic and environmental), in a tissue-specific manner, to trigger or sustain a disease cascade, which ultimately results in the cell and synaptic loss observed in AD.
Journal ArticleDOI
Monoaminergic neuropathology in Alzheimer's disease.
Goran Šimić,Mirjana Babić Leko,Selina Wray,Charles R. Harrington,Ivana Delalle,Nataša Jovanov-Milošević,Danira Bažadona,Luc Buée,Rohan de Silva,Giuseppe Di Giovanni,Claude M. Wischik,Patrick R. Hof +11 more
TL;DR: Special emphasis is given to the serotonergic dorsal raphe nucleus (DRN) and noradrenergic LC, among the first to be affected by tau protein abnormalities in the course of sporadic AD, causing behavioral and cognitive symptoms of variable severity.
References
More filters
Journal ArticleDOI
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
TL;DR: A clear beneficial effect of rivastigmine was shown on cognitive function for patients with mild AD and plasma values of ChE inhibition were associated with attention.
Journal ArticleDOI
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
TL;DR: Use of the rivastigmine transdermal patch in patients on established memantine appears to be well-tolerated, with only modest, non-significant increases in AEs compared with monotherapy, and did not seem to affect cognition or global functioning adversely.
Journal ArticleDOI
Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
TL;DR: Long-term systemic administration of anti-APP β-site antibodies to Tg2576 transgenic mice improved mouse cognitive functions associated with a reduction in both brain inflammation and the incidence of microhemorrhage, and antibody treatment did not induce any peripheral autoimmunity responses.
Journal ArticleDOI
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before
TL;DR: The discovery of new drugs efficacious in AD subjects is an ambitious goal, however, and one that will require close, active collaboration by pharmacologists, chemists and clinicians.
Journal ArticleDOI
Clinical observations with AN-1792 using TAPIR analyses.
Christoph Hock,Roger M. Nitsch +1 more
TL;DR: Clinical observations with AN-1792 using tissue amyloid plaque immunoreactivity (TAPIR) analyses established for the first time evidence in humans that antibodies against β-amyloid-related epitopes are capable of slowing progression in Alzheimer’s disease.
Related Papers (5)
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
John Hardy,Dennis J. Selkoe +1 more
Neuroinflammation in Alzheimer's disease
Michael T. Heneka,Monica J. Carson,Joseph El Khoury,Gary E. Landreth,Frederic Brosseron,Douglas L. Feinstein,Andreas H. Jacobs,Tony Wyss-Coray,Tony Wyss-Coray,Javier Vitorica,Richard M. Ransohoff,Karl Herrup,Sally A. Frautschy,Bente Finsen,Guy C. Brown,Alexei Verkhratsky,Alexei Verkhratsky,Alexei Verkhratsky,Koji Yamanaka,Jari Koistinaho,Eicke Latz,Eicke Latz,Annett Halle,Gabor C. Petzold,Terrence Town,Dave Morgan,Mari L. Shinohara,V. Hugh Perry,Clive Holmes,Clive Holmes,Nicolas G. Bazan,David J. Brooks,Stéphane Hunot,Bertrand Joseph,Nikolaus Deigendesch,Olga Garaschuk,Erik Boddeke,Charles A. Dinarello,John C.S. Breitner,Greg M. Cole,Douglas T. Golenbock,Markus P. Kummer +41 more